Lupin signs second partnership for its oncology pipeline, this time with German drug maker BI
BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially treat patients of skin and stomach cancer.
Indian pharma major Lupin and German drug maker Boehringer Ingelheim (BI) will come together to work on a cure for cancers which has never been treated before. BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially treat patients of skin and stomach cancer. Lupin will receive an upfront payment of $20 million with potential additional payments upto $700 million upon successful achievement of defined clinical, reclinical, regulatory and commercial milestones. The company is also expected to receive double-digit royalties on the sales of the product upon commercialisation which would take at least seven years.
The partnership will compliment BI’s ongoing innovation on the new pathway called the KRAS inhibitors, which several drug companies across the world are chasing in the last few years. KRAS is a gene that suppresses the proliferation of cells, however a mutated KRAS gene leads to cell proliferation causing cancer. Lupin’s head of drug discovery programe Raj Kamboj thinks that its own MEK inhibitor helps it to pair it with the KRAS inhibitor of BI to develop a new combination treatment. KRAS mutattations occur in 1 in 7 of all human metastatic cancers making it the most frequently mutated cancer-causing gene, with mutation rates of more than 90 percent in pancreatic cancers, more than 40 percent in colorectal cancers and more than 30 percent in lung adenocarcinomas. “No body is working on this combination”, Kamboj told to press on Wednesday. Lupin’s MD Nilesh Gupta added that the company decided to take this drug forward as its molecule cleared early clinical stages.
Lupin added that its preclinical data has shown that the combination of BI’s novel KRAS inhibitors with MEK inhibitors results in increased anti-tumor activity based on their complementary mechanisms of action in keeping KRAS-driven cancers in check. Additionally Lupin’s MEK inhibitors developed as part of its oncology pipeline have shown pre-clinical activity as a single agent as well as in combination. Furthermore, they have also shown early clinical benefit in a small subset of patients The company did not disclose in how many patients did it test the drug. Some of the other companies working on the similar pathway are drug makers like Amgen, Johnson & Johnson, Mirati among others who are aggressively pursuing this science. Lupin is expecting to spend 10 percent of its revenues in R&D in the coming quarters. Last year Lupin had signed a similar agreement with global drug maker AbbVie to develop and commercialise immunotherapy drugs to treat cancer. The company said that JV is progressing well. On Wednesday shares of Lupin closed at Rs 741 down by 0.86%.
Source:https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-signs-second-partnership-for-its-oncology-pipeline-this-time-with-german-drug-maker-bi/articleshow/70978748.cms
Indian pharma major Lupin and German drug maker Boehringer Ingelheim (BI) will come together to work on a cure for cancers which has never been treated before. BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially treat patients of skin and stomach cancer. Lupin will receive an upfront payment of $20 million with potential additional payments upto $700 million upon successful achievement of defined clinical, reclinical, regulatory and commercial milestones. The company is also expected to receive double-digit royalties on the sales of the product upon commercialisation which would take at least seven years.
The partnership will compliment BI’s ongoing innovation on the new pathway called the KRAS inhibitors, which several drug companies across the world are chasing in the last few years. KRAS is a gene that suppresses the proliferation of cells, however a mutated KRAS gene leads to cell proliferation causing cancer. Lupin’s head of drug discovery programe Raj Kamboj thinks that its own MEK inhibitor helps it to pair it with the KRAS inhibitor of BI to develop a new combination treatment. KRAS mutattations occur in 1 in 7 of all human metastatic cancers making it the most frequently mutated cancer-causing gene, with mutation rates of more than 90 percent in pancreatic cancers, more than 40 percent in colorectal cancers and more than 30 percent in lung adenocarcinomas. “No body is working on this combination”, Kamboj told to press on Wednesday. Lupin’s MD Nilesh Gupta added that the company decided to take this drug forward as its molecule cleared early clinical stages.
Lupin added that its preclinical data has shown that the combination of BI’s novel KRAS inhibitors with MEK inhibitors results in increased anti-tumor activity based on their complementary mechanisms of action in keeping KRAS-driven cancers in check. Additionally Lupin’s MEK inhibitors developed as part of its oncology pipeline have shown pre-clinical activity as a single agent as well as in combination. Furthermore, they have also shown early clinical benefit in a small subset of patients The company did not disclose in how many patients did it test the drug. Some of the other companies working on the similar pathway are drug makers like Amgen, Johnson & Johnson, Mirati among others who are aggressively pursuing this science. Lupin is expecting to spend 10 percent of its revenues in R&D in the coming quarters. Last year Lupin had signed a similar agreement with global drug maker AbbVie to develop and commercialise immunotherapy drugs to treat cancer. The company said that JV is progressing well. On Wednesday shares of Lupin closed at Rs 741 down by 0.86%.
Source:https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-signs-second-partnership-for-its-oncology-pipeline-this-time-with-german-drug-maker-bi/articleshow/70978748.cms
Comments
Post a Comment